Tolrestat

DB02383ApprovedWithdrawnSmall molecule

Tolrestat (INN) (AY-27773) is an aldose reductase inhibitor which was approved for the control of certain diabetic complications. While it was approved for marketed in several countries, it failed a... It was sold under the tradename Alredase but was discontinued by Wyeth in 1997 because of the risk of severe liver toxicity and death.

Chemical structure of Tolrestat
Mechanism
Curator reviewed
Primary indication
For the pharmacological control of certain diabetic complications.Curator reviewed
Formula / weight
C16H14F3NO3S · 357.347 g/mol (avg)
Code names
AY-27,773

Resolves to

Compound
UNII0T93LG5NMKCAS82964-04-3ChEMBLCHEMBL436ChEBI48549PubChem53359KEGGD02323
Clinical / RWD
RxNorm38386ATCA10XA01
Structure
InChIKeyLUBHDINQXIHVLS-UHFFFAOYSA-NSMILESCOC1=C(C2=CC=CC(C(=S)N(C)CC(O)=O)=C2C=C1)C(F)(F)F
Targets
P15121AKR1B1Q99720SIGMAR1P14550AKR1A1O60218AKR1B10

What you can answer from here — as of September 13, 2026

4Protein targetsEach mapped to UniProt, with action and pharmacological action
Listed above
558Drug interactionsStructured to mechanism, not free text
Sign in
1ATC codeIncluding every combination product, plus 7 drug categories
Sign in
20+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Tolrestat, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In